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Abstract
Ivermectin (Mectizan®) is the only drug currently recommended for the treatment and control of
onchocerciasis. Serious adverse events rarely occur during treatment, except in subjects heavily
infected with Loa Loa. This review of drug-related serious adverse events in the treatment of
onchocerciasis therefore revisited the pre-Mectizan® reference drugs, DEC and suramin, and other
candidate drugs studied extensively for the treatment of human onchocerciasis. The benzimidazole
carbamate derivatives and the antibiotic doxycycline were excluded, since no serious adverse
events have been reported regarding their use. Using recommended definitions, serious adverse
events reported or observed after the use of each drug were summarised, the level of attribution
determined, and the results tabulated. Prominence was given to treatment-related deaths. The
clinical picture of severe symptomatic postural hypotension is described and used to illustrate the
difference between the severity and the seriousness of an adverse event. The epidemiology,
management and outcome of serious adverse events are presented. The role of future research is
discussed.
Introduction
The efforts made through more than four decades of
research yielded ivermectin (Mectizan®) as the only drug
to be recommended for the treatment and control of
onchocerciasis. The activity against the microfilariae (mf)
of Onchocerca volvulus in a single dose of 150–200 µg/kg
[1], and against the adult worms on repeated dosage [2–
6], testifies to the efficacy of the drug. The distribution,
monitoring and management of adverse events in the
community by individuals with little medical knowledge
are proof that Mectizan® rarely produces Serious Adverse
Events (SAEs) in the onchocerciasis patient. Hence, this
contribution to the clinical spectrum of drug-related seri-
ous adverse events in the treatment of onchocerciasis also
examines the pre-Mectizan® "reference" drugs, diethylcar-
bamazine (DEC) and suramin, and other drugs studied
extensively for the treatment of human onchocerciasis.
The drugs and their effects against O. volvulus are listed
and summarised in Table 1. There have been no SAEs
attributed to mebendazole [7,8], flubendazole [9] alben-
dazole [10–12] or doxycycline [13]. They will therefore
not be considered further. In addition, little reference will
be made to melarsonyl potassium (not listed) – a potent
macrofilaricide that resulted in death from arsenical
encephalopathy [14,15].
Definitions
Serious Adverse Event (SAE)
As defined in the International Conference on Harmoni-
sation of Technical Requirements for Registration of Phar-
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maceuticals for Human Use (ICH) Harmonised Tripartite
Guideline for Good Clinical Practice [16], a serious
adverse event is "any untoward medical occurrence that,
at any dose a) results in death b) is life-threatening c)
requires inpatient hospitalisation or prolongation of an
existing hospitalisation d) results in persistent or signifi-
cant disability/incapacity or e) is a congenital anomaly/
birth defect." A modification to these criteria [17] has
included important medical events that may not be
immediately life threatening, or result in death or hospi-
talisation, but that may jeopardize the patient, or require
intervention to prevent the other outcomes listed above.
Causality or Attribution
When an adverse event is recorded, the relationship to the
medicinal product (causality) needs to be determined, as
this has important implications for the future use of the
product. Various terms define this relationship. One such
set of definitions [17] is as follows:
1) Not related: The experience is clearly related to other
factors such as the patient's clinical state, therapeutic
intervention or concomitant therapy.
2) Unlikely: The experience was most probably produced
by other factors, such as the patient's clinical state, thera-
peutic intervention or concomitant therapy, and does not
follow a known response pattern to the trial product.
3) Possible: The experience follows a reasonable temporal
sequence from the time of product administration, and/or
follows a known response pattern to the trial product, but
could have been produced by other factors such as the
patient's clinical state, therapeutic intervention or con-
comitant therapy.
4) Probable: The experience follows a reasonable tempo-
ral sequence from the time of product administration,
and/or follows a known response pattern to the trial prod-
uct, and could not have been produced by other factors
such as the patient's clinical state, therapeutic intervention
or concomitant therapy.
5) Most probable: The experience follows a reasonable
temporal sequence from the time of product administra-
tion, and/or follows a known response pattern to the trial
product, and could not have been produced by other fac-
tors such as the patient's clinical state, therapeutic inter-
vention or concomitant therapy, and  either occurs
immediately following trial product administration, or
improves on stopping the product, or there is positive
reaction at the application site.
With the drugs under consideration, adverse events that
resulted in death will be summarised, followed by other
categories of SAEs and the determination and discussion
Table 1: Drugs and their activity against Onchocerca volvulus
Chemical group Effect on O. volvulus
Microfilariae Adult worms
Lethal effect Lethal effect Embryo-Toxicity/depletion Embryo-sequestration*
Avermectin
Mectizan® ++++ 0 to ++** 0 to ++** ++++
Urea derivative
Suramin +++ ++++ ++++ 0
Piperazine derivative
Diethylcarbamazine ++++ 0 0 0
Organophosphate
Metrifonate +++ 0 0 0
Benzimidazole carbamate
Mebendazole ++ 0 ++ 0
Flubendazole 0 0 ++ 0
Albendazole 0 0 +++ 0
Thiourea
Amocarzine† +++ 0 0 0
Tetracycline
Doxycycline‡ 0 0 ++++ 0
* A block to the release of microfilariae is the primary effect, followed by their degeneration in utero ** On multiple dosage † Not registered ‡ 
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of causality. Although they are described under separate
systems, adverse events tend to be multi-systemic.
SAEs associated with various drugs
Deaths
The administration of a total dose of 10 g of suramin over
a period of 19 days to 20 patients resulted in four deaths
[18]. Doses in excess of 6.0 g have also resulted in death
[19–21]. These were due to over-dosage. However, the
deaths of two patients who were treated with what would
be currently acceptable doses [22] were also probably due
to drug effects. In both cases, the patients complained of
oropharyngeal pain, refused to eat or drink and had pro-
longed diarrhoea; there was no response to corticosteroid
therapy. Reports of death in 11% of 592 treated patients,
occurring six years after completion of a total dose of 10 g
of suramin, [23] and after four years in 6% and 18% of
patients in two hyper-endemic villages treated with a total
dose of 4–6 g of suramin [22] were possibly related to
therapy. Death also occurred in 7 out of 327 patients
treated with DEC [24]. All the patients were in poor gen-
eral health, were malnourished, and had underlying
chronic medical conditions. They all lapsed into a coma
after taking 225 – 900 mg of the drug over 3 to 8 days, and
died 1 to 4 days after the onset of the coma. There was no
classical Mazzotti reaction and they failed to respond to
supportive therapy and corticosteroids. A young man
given low dose DEC under betamethasone cover [25] died
on the third day in a state of shock and respiratory dis-
tress. His liver and spleen were moderately enlarged prior
to treatment. In these DEC-related deaths, it is unlikely
that the drug was the cause. The event was most probably
produced by other factors, such as the patient's clinical
state, other therapeutic intervention or concomitant ther-
apy, and did not follow the known response pattern to
DEC. Similarly, the death of an elderly woman from
chicken pox two weeks after completing a DEC plus beta-
methasone course [25] was unlikely to be due to DEC.
Syndromes of collapse and "therapeutic shock"
This brings together accounts of life threatening clinical
situations that followed treatment with DEC. They were
associated with prostration, syncope, collapse and hypo-
tension [26–28]. The term "therapeutic shock" was coined
to describe the clinical status of the patient [29]. These
were desperately ill patients with multi-system
involvement.
A related but distinct adverse effect is severe symptomatic
postural hypotension (SSPH). In the classical case, the
pulse and blood pressure are normal while recumbent.
On standing for a short while (a few minutes), there is diz-
ziness, weakness or faintness and the patient becomes
restless or confused; occasionally syncope occurs. The
pulse rate increases in successive recordings, gets fainter
and becomes impalpable, whilst blood pressure falls in a
similar fashion. On assuming the recumbent position,
bradycardia, drowsiness and diaphoresis occur. [30]. Usu-
ally, recovery follows rapidly and no treatment is neces-
sary. SSPH has been described after treatment with
virtually all microfilaricides except mebendazole [30–33].
It is one of the few adverse events that occurred to the
same extent when equipotent doses of DEC and Mectizan®
were given to patients with similar intensities of infection
with O. volvulus [34]. SSPH is, par excellence, a "severe"
adverse event that is usually not "serious" since it is so
readily and simply reversible. During the field trials of
Mectizan® conducted by the Onchocerciasis Control Pro-
gramme (OCP) http://www.who.int/ocp/, several cases of
SSPH were recorded in the early stages. The incidence fell
dramatically when patients who felt weak or dizzy were
asked to remain recumbent and send for the nurse rather
than walk to the monitoring station [35]. However, in a
few subjects, multiple episodes occur in quick succession.
Under these circumstances, intervention that is more spe-
cific is required, in order not to jeopardize the patient. It
is only then that SSPH becomes an SAE. Two patients who
suffered "severe sustained postural hypotension" after
Mectizan® [36] fall into this category.
Idiosyncratic reactions
Rarely, collapse with nausea, vomiting, shock, sweating
and loss of consciousness have followed the initial injec-
tion of suramin [37]. As a precaution, a test dose of 100–
200 mg (1 to 2 ml of a 10% solution) injected slowly over
3 minutes was advocated [38].
Dermatology/Skin
Adverse skin reactions to microfilaricides rarely justify
hospitalisation, except where extensive secondary infec-
tion has followed prolonged scratching. An exception
occurs when patients with hyper-reactive onchodermatitis
are treated with any microfilaricide. This may result in
severe, prolonged itching, an extensive oedema of the
skin, and limb swelling. In one report, repeated intrave-
nous corticosteroid injections over 3 days were required to
control symptoms [39]. Exfoliative dermatitis is an
uncommon late manifestation of suramin therapy
[22,40]. A patient treated with suramin in northern
Ghana developed exfoliative dermatitis and the palms of
the hands and the soles of the feet came off as complete
casts ("suramin casts"; Awadzi, unpublished
observation).
Lymphatic
Extensive swelling of lymph glands, commonly in the
groins, with oedema of the overlying skin extending over
the pubis and lower abdomen occurs in heavily infected
patients treated with DEC or metrifonate and, rarely, with
Mectizan®. Pain is often severe and patients are unable toFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S6
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turn over in bed due to reflex flexion of the hips. At best,
they assume the "knee elbow position". They also become
rooted to the spot when asked to walk – the "pillar of salt
effect" [41].
Gastrointestinal
The administration of metrifonate daily for three or more
days resulted in very severe abdominal colic due to the
muscarinic effects of accumulated acetylcholine. In one
study, abdominal pain occurred in 20 out of 34 patients
and was unaffected by belladonna alkaloids started orally
two days before and continued for a week. The pain per-
sisted for several days after the completion of treatment
[42].
Ulceration of the gastrointestinal tract rarely occurs with
suramin. Stomatitis was observed in 1 of 100 patients
treated [22]. Much more extensive ulceration was
observed in one patient treated in northern Ghana
(Awadzi, unpublished observation). Chronic diarrhoea
was always an ominous sign of suramin toxicity. A his-
topathological examination of a chimpanzee after treat-
ment with the equivalent of a 9 g dose of suramin for
humans showed the intestines to be the organ most
severely affected [43]. These gastrointestinal manifesta-
tions were probably due to over-dosage.
Pulmonary
During the OCP Mectizan® trials, in which more than
50,000 persons were treated, life threatening dyspnoea
occurred in three patients within 24 hours of treatment
[35]. Two were known asthmatics. The author was present
during these attacks. One, a young male adult, had expe-
rienced asthmatic attacks previously but these had always
responded to paracetamol; the post-Mectizan® attack did
not. The other, a young adult female had attacks usually at
the time of the full moon. Her attack occurred when the
moon was full but was much more severe than previously.
Multiple episodes occurred and she required intravenous
aminophylline injections plus betamethasone therapy.
Multiple attacks also occurred in a known asthmatic dur-
ing the hospital-based trials (Awadzi, unpublished obser-
vation). These episodes were possibly related to Mectizan®
therapy. The third patient with dyspnoea was a young
adolescent male who had laryngeal oedema following an
upper respiratory tract infection. His attack was not
related to Mectizan®  therapy. Recurrent bronchospasm
requiring adrenaline therapy occurred 6 hours after treat-
ment with metrifonate in a patient with no previous his-
tory [44]. Here also, the attack was possibly related to
therapy.
Ulceration of the tracheobronchial tree is a rare manifes-
tation of suramin toxicity. In one unpublished case from
northern Ghana, expectoration of a "cast" of a bronchus
composed of mucus and blood was observed. The same
patient had produced casts of the soles and palms referred
to above. He also had stomatitis and buccal ulceration.
These manifestations resulted from over-dosage due to an
error in the calculation of the total dose of suramin.
Musculoskeletal
A severely painful, acute polyarthritis involving mainly
the knees, ankles, wrists, small joints of the fingers, and
the elbows has been described following treatment with
metrifonate and DEC. It began several days after the onset
of therapy, when the peak of the initial reaction had
passed, and hence was termed a "secondary reaction"
[34,42]. Associated features were fever, sterile joint effu-
sions with polymorphonuclear cells and microfilariae,
and a raised erythrocyte sedimentation rate. Such adverse
events have not been reported with Mectizan®. A similar
syndrome with a sub-acute course occurred late during
suramin therapy or during the post treatment observation
phase. In addition, painful immobilisation of the hip
joint in a semi-flexed position has been described. This
was attributed to a reaction around dead worm bundles
lying against the capsule of the joint [45].
Neurological
Cerebral toxicity occurred when the total dose of amocar-
zine given within 48 hours in the fasting state was 30 mg/
kg or greater. When given after a meal, similar effects
occurred at 25 mg/kg [46]. This involved 8 out of 39
patients (5/9 at 45 mg, 2/20 at 30 mg/kg and 1/10 at 25
mg/kg). There was mental confusion in all 8 patients. At
45 mg/kg, two patients performed repetitive extension
movements of the neck, arms and legs while "searching
movements" with the arms occurred in one markedly apa-
thetic patient. Another patient was extremely aggressive
and had to be restrained. Other features were inappropri-
ate jocularity, perseveration, failure to concentrate, drow-
siness and incontinence. The onset was 30 hours or more
after drug administration, lasted from one to 47 hours
and was followed by a complete recovery. These adverse
events were attributed to the pharmacological properties
of the drug.
Vertigo with prostration and incapacitation has been
attributed to the mobilisation of microfilariae into the
cerebrospinal fluid. The associated headache, nausea and
vomiting may also have been of a central nervous system
origin. A Parkinsonian-like syndrome lasting for seven
days was also observed [47].
Marked proximal muscle weakness involving the neck,
shoulder and pelvic girdles, with retention of distal mus-
cle function, occurred after the fifth of a planned six daily
dose regimen in one patient treated with metrifonate [42].
There was no sensory deficit. He was bedridden for 3 days.Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S6
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The last dose was omitted. The event was attributed to the
nicotinic effects of accumulated acetylcholine.
Constitutional symptoms and other systemic features
Fever, fatigue, general weakness and, rarely, prostration of
short duration occur after treatment with microfilaricides.
However, with suramin therapy they may be prolonged
and herald a grave prognosis. The occurrence of jaundice
with amocarzine [46] and suramin therapy [48] was
unlikely to be due to drug therapy. Despite the frequency
of proteinuria with suramin therapy, no renal associated
SAEs have been documented.
Ocular/Visual
Anterior segment inflammation, with iridocyclitis, poste-
rior synechiae and secondary glaucoma, and involvement
of the posterior segment with optic neuritis, optic atrophy
and visual field defects, have occurred following treat-
ment with DEC and suramin. Lesions of the posterior seg-
ment occurred early with DEC treatment [49]. Fluorescein
angiography demonstrated leakage of dye from the optic
disc and disturbances of the retinal pigment epithelium
before ophthalmoscopic changes were apparent [50].
Anterior segment lesions due to suramin did not occur for
several weeks and optic atrophy developed after several
months [51,52].
Epidemiology of drug-related SAEs in the treatment of 
onchocerciasis
Adverse effects occurring during the treatment of
onchocerciasis may be due to:
1) The intrinsic properties of the drug
2) Therapeutic misadventure
3) The effect on the parasite-microfilariae (death-mobili-
sation into body fluids), and rarely to the death of the
adult worms
4) A progressive disability from pre-existing lesions
5) A coincidental illness occurring in temporal relation-
ship with drug administration or
6) Other factors.
With suramin, metrifonate and amocarzine, intrinsic drug
effects are combined with parasite factors in the genera-
tion of the adverse events.
Intrinsic properties of the drug
Adverse events may be an expression of the pharmacolog-
ical properties of the drug. They may have little to do with
efficacy against the parasite. The event could be a manifes-
tation of over-dosage either due to pure guesswork in the
selection of the dose regimen, as occurred in the early days
of suramin therapy [18], to an error in dispensing or
administration, as occurred with the Ghanaian patient
mentioned above, or to a direct extrapolation of data from
animal experiments. In the cattle O. gibsoni model, amo-
carzine was macrofilaricidal at a dose of 40 mg/kg given
daily for 3 days [53]. The equivalent dose in man would
be 2000 – 2400 mg given daily for 3 days (total 6000 –
7200 mg). Single doses up to 1600 mg were shown to be
safe in the fasting state. However, when 1200 mg were
given daily for 2 days (total 2400 mg), severe cerebrotox-
icity occurred in 5/9 patients, without any manifestation
of a macrofilaricidal effect [46]. On the other hand, SAEs
could follow an inexplicable pattern, as occurred during
the use of melarsonyl potassium [14,15]
Therapeutic misadventure
Several factors need to be considered in the treatment of
any disease, especially if the outcome is not fatal. Here,
the application of basic therapeutic principles must pre-
dominate over the urge to treat. The health care provider
must decide:
1) Whether the patient should be interfered with
2) What alteration in the patient's status one hopes to
achieve
3) What other effects the drug may have and whether
these would be harmful
4) Whether the likelihood of benefit outweighs the likeli-
hood of damage.
The general medical status of the patient and the presence
of coexisting medical conditions greatly influence the out-
come of therapy, especially with drugs such as suramin
[38]. Some fatalities in the treatment of onchocerciasis
may have been due to a lack of consideration of these
principles.
Parasite death
For a given dose of a microfilaricide, parasite related SAEs
are more likely to occur in patients with high skin and
ocular microfilarial loads [35,54]. The reduction in high
microfilarial counts in skin predisposes to events that
result in hospitalisation or prolongation of existing hospi-
talisation, while involvement of the ocular/visual system
could result in persistent incapacity or disability. Addi-
tional factors are the concatenation of severe reactions
involving multiple systems, such as occurred in patients
with "therapeutic shock" and the coexistence of other
filarial parasites, especially L. loa [55]. GastrointestinalFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S6
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parasites do not appear to contribute significantly to
increased morbidity [56].
Other factors
Suramin has important intrinsic toxicity and some of the
deaths during the treatment of onchocerciasis have been
difficult to explain. However, a proportion of its adverse
reputation in onchocerciasis have been due to a "transfer"
of SAEs observed in the treatment of trypanosomiasis and
pemphigus [48].
The linkage of SAEs to Causality
The attribution of SAEs to the administered drug or trial
product requires a consideration of the following factors:
1) Temporal relationship between the administration of
the drug and the adverse event.
2) The known response pattern to the drug
3) The subject's underlying clinical state, other therapeutic
intervention and concomitant therapy
4) Response to de-challenge (discontinuation of the drug)
and re-challenge (repeat exposure to the drug).
In many of the drug-related SAEs described, re-challenge
was not possible, practicable or justifiable. Hence, the
highest level of attribution (Level 5 or "most probable"),
as defined previously, could not be allocated. Otherwise,
Table 2: Onchocerciasis – SAEs, Drugs administered and the Level of Attribution
Category/Adverse event Drug and Level of Attribution*
Mectizan® DEC Metrifonate Suramin Amocarzine
Death 1 2 1 4** 1
Syndromes of collapse
"Therapeutic shock" 1 4 4 1 1
Recurrent SSPH 4 4 4 1 4
I d i o s y n c r a t i c 11141
Dermatology/Skin
Hyper-reactive response 4 4 1 1 1
Exfoliative dermatitis 1 1 1 4 1
Lymphatic syndromes 4 4 4 1 4
Gastrointestinal
Abdominal colic 1 1 4 1 1
GIT† ulceration 1 1 1 4 1
Chronic diarrhoea 1 1 1 4 1
Pulmonary
Bronchospasm 3 1 3 1 1
Bronchial ulceration 1 1 1 4 1
Musculoskeletal
Acute polyarthritis 1 4 4 1 1
Subacute polyarthritis 1 1 1 4 1
Hip immobilization 1 1 1 4 1
Neurological
Cerebrotoxicity 1 1 1 1 4
V e r t i g o 13111
Parkinsonian-like state 1 3 1 1 1
Proximal muscle weakness 1 1 4 1 1
Constitutional symptoms
Prolonged fever 1 1 1 4 1
Prolonged fatigue 1 1 1 4 1
A s t h e n i a 11141
P r o s t r a t i o n 14141
Hepatic
Jaundice 1 1 1 2 2
Ocular/visual incapacity 1 4 1 4 1
* Level of attribution 1 = not related (or not described); 2 = unlikely; 3 = possible; 4 = probable; 5 = most probable ** Late deaths possibly related 
to treatment (Level 3). †GIT = gastrointestinal tractFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S6
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these SAEs are summarised in Table 2, together with the
assigned levels of attribution.
Outcome
When the deaths due to over-dosage with suramin and
therapeutic misadventures are discounted, drug-related
SAEs in the treatment of onchocerciasis rarely include
fatalities. SAEs due to the intrinsic toxicity of metrifonate
and amocarzine are completely reversible over several
days; those due to suramin may last for several weeks.
Most of the SAEs associated with the death of microfilar-
iae either resolve spontaneously or respond favourably to
therapy within a few days, without any disability or inca-
pacity. The major exception is the effect on the ocular/vis-
ual system where visual field loss can be severe (tunnel
vision) and irreversible.
Corticosteroids have been used, aided by supportive ther-
apy, in many categories of SAEs. The main indication has
been the general status of the patient. Thus, they have
been used in patients who are desperately ill or in a state
of shock, in patients with multiple episodes of SSPH, in
the cerebrotoxicity of amocarzine and for the ulcerative
lesions and prostration following suramin therapy. When
indicated after microfilaricidal therapy, our practice has
been to give a single dose of 200 mg of hydrocortisone
sodium hemisuccinate intravenously. Only occasionally
has the patient required a second dose. However, with the
cerebrotoxicity of amocarzine, this dose was given every 2
hours for 6 to 8 hours. The effect was not as dramatic as
with other SAEs. A short course of betamethasone was
needed for one of the asthmatics during the OCP studies.
Corticosteroid eye drops are needed in the iridocyclitis
following DEC or suramin to prevent the formation of
adhesions.
The acute polyarthritis of the "secondary phase" responds
favourably to paracetamol or aspirin and corticosteroids
are not needed. Lymphatic lesions also respond but less
promptly. Other drugs used were antihistamines for pru-
ritus and atropine for the abdominal colic of metrifonate.
Conclusions
In the absence of Loa loa infection, the treatment of
onchocerciasis with Mectizan® rarely results in SAEs. Most
of this presentation therefore focused on a systematic
review of SAEs following treatment with DEC, suramin,
metrifonate and amocarzine. The benzimidazole car-
bamate derivatives – mebendazole and albendazole – and
the antibiotic doxycycline were not considered, as SAEs
were never reported. SAEs associated with suramin, DEC
and amocarzine were considerable; in some cases, they
were fatal. They serve to emphasise the major leap that
occurred with the introduction of Mectizan® for the treat-
ment and control of onchocerciasis. Mectizan® has elimi-
nated the use of DEC (except as a diagnostic agent in the
"patch test") and left little justification for the use of
suramin. The rarity of SAEs with Mectizan® has made com-
munity distribution, by those with little more than the
capacity to keep records, feasible. Although Mectizan® has
the unique ability to eliminate high microfilarial loads
with minimal or no adverse effects, serious adverse events
do occur occasionally and care is still needed when the
heavily infected Mectizan®-naïve are to be treated. The
pathogenesis of the adverse effects remains unknown and
requires study. The elucidation is likely to be complex
because any proposed mechanisms [57–64] need to
explain why Mectizan®, a potent microfilaricide, differs so
radically from other agents in the onset, course and sever-
ity of adverse events, and the lack of "secondary reac-
tions". A practical consideration is how a knowledge of
the pathogenesis will impact on the use of Mectizan® in
the field.
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